FDA Approves Lilly's Ebglyss (lebrikizumab-lbkz) for Atopic Dermatitis Treatment
核心洞察
The FDA has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for treating moderate-to-severe atopic dermatitis (搜索) (eczema (搜索)) in patients 12 years and older.
Ebglyss, a targeted IL-13 (搜索) inhibitor, is administered as a monthly injection after an initial treatment phase to reduce eczema (搜索) inflammation.
Clinical trials demonstrated that Ebglyss led to clear or almost clear skin in 38% of patients at 16 weeks, with sustained results in a majority at one year.
Eli Lilly and Company has received FDA approval for Ebglyss (lebrikizumab-lbkz) for the treatment of moderate-to-severe atopic dermatitis (搜索) in patients aged 12 and older, who weigh at least 40kg, whose eczema (搜索) is not well controlled with topical therapies. This approval marks a significant advancement in eczema treatment, offering a targeted approach to reduce inflammation and improve patient outcomes.
Targeted IL-13 Inhibition
Ebglyss is a targeted IL-13 (搜索) inhibitor designed to combat eczema (搜索) inflammation throughout the body, addressing the root causes of dry, itchy, and irritated skin. The drug is administered via injection, providing a convenient monthly maintenance dose following an initial treatment phase. The recommended starting dose is 500mg (two 250mg injections), followed by 250mg every two weeks until Week 16 or later when adequate clinical response is achieved. A single monthly injection of 250mg every four weeks is recommended as maintenance.
Clinical Trial Data
The FDA approval was based on data from the ADvocate 1, ADvocate 2, and ADhere studies, which included over 1,000 adults and children with moderate-to-severe eczema (搜索). The primary endpoint of these studies was clear or almost clear skin at 16 weeks. Results indicated that, on average, 38% of patients receiving Ebglyss achieved clear or almost clear skin at 16 weeks, with 10% experiencing this within four weeks, compared to 12% in the placebo group. Furthermore, 77% of those who achieved clear or almost clear skin at Week 16 maintained these results at one year with once-monthly dosing. Itch relief was also significant, with 43% of Ebglyss recipients reporting relief at 16 weeks, compared to 12% with placebo.
Safety Profile and Considerations
Common side effects associated with Ebglyss include eye and eyelid inflammation (redness, swelling, itching), injection site reactions, and shingles. The drug is contraindicated for individuals allergic to lebrikizumab-lbkz or any of its ingredients. Patients are advised to consult with their healthcare providers regarding potential risks and benefits.
Market Availability and Support
Lilly plans to commercialize Ebglyss in the U.S. in the coming weeks and is collaborating with insurers, health systems, and providers to ensure patient access. The company will offer 'Lilly Support Services for Ebglyss,' a patient support program that includes co-pay assistance for eligible, commercially insured patients. Ebglyss has already been approved in the European Union and Japan, with additional market approvals anticipated later this year. Lilly holds exclusive rights to develop and commercialize Ebglyss in the U.S. and other territories outside Europe, where Almirall holds the rights.